Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patien...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Endocrinology Research Centre 2015-12-01
Sarja:	Сахарный диабет
Aiheet:	type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life
Linkit:	https://www.dia-endojournals.ru/jour/article/view/7695
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!